Bio-Better Outcome On Biosimilars For FDA In Senate Funding Report
This article was originally published in The Pink Sheet Daily
Executive Summary
Pressure on agency to finalize biosimilar guidances is still there, but unlike in the House, the Senate doesn't set the deadlines.
You may also be interested in...
FDA Field Operations Would Endure Reductions Under Budget
President Obama’s FY 2016 blueprint includes cuts to ‘low-priority’ enforcement, surveillance and other activities in FDA human drugs and biologics programs, but still increases those operations overall.
‘Precision Medicine’ Gets R&D Funding Push In President’s Speech
President Obama highlights potential for personalized medicine in his State of the Union address and will seek a “major increase” in research and development funding.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.